ProMetic Life Sciences Inc. (PLI) Rating Reiterated by Scotiabank
ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating reaffirmed by Scotiabank in a research report issued on Tuesday. They currently have a C$5.00 price objective on the stock. Scotiabank’s target price indicates a potential upside of 105.76% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the company. CIBC lowered their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. TD Securities reissued a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research note on Wednesday, November 16th. Royal Bank Of Canada reissued an “outperform” rating on shares of ProMetic Life Sciences in a research note on Thursday, August 25th. Canaccord Genuity lifted their target price on ProMetic Life Sciences from C$4.50 to C$4.75 and gave the company a “buy” rating in a research note on Friday, November 18th. Finally, Bloom Burton reissued a “hold” rating on shares of ProMetic Life Sciences in a research note on Thursday, October 13th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. ProMetic Life Sciences has a consensus rating of “Buy” and a consensus target price of C$4.84.
ProMetic Life Sciences (TSE:PLI) opened at 2.43 on Tuesday. ProMetic Life Sciences has a 52-week low of $1.88 and a 52-week high of $3.62. The firm’s market capitalization is $1.51 billion. The company’s 50-day moving average price is $2.81 and its 200 day moving average price is $2.90.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.